齐拉西酮与氟哌啶醇治疗精神分裂症激越症状的效果及安全性比较

Comparison of curative effects and safety of ziprasidone and haloperidol in treatment of schizophrenia agitation

目的探讨齐拉西酮与氟哌啶醇治疗精神分裂症激越症状的效果及安全性比较。方法选取医院2017年1月~2018年12月收治80例精神分裂症伴激越症状患者,随机分为观察组和对照组各40例,对照组给予氟哌啶醇,观察组给予齐拉西酮。治疗前后,评估两组患者阳性与阴性症状评分(PANSS)、阳性与阴性症状兴奋因子(PANSS-EC)、认知功能评分(WMS、TMT),并记录两组患者不良反应事件。结果治疗后,两组PANSS与PANSS-EC评分均优于治疗前(P<0.05),但两组间比较差异无统计学意义(P>0.05);治疗后,观察组患者WMS、TMT评分情况均优于对照组(P<0.05);治疗后,两组患者不良反应发生率差异无统计学意义(P>0.05),但观察组稍好于对照组。结论应用齐拉西酮与氟哌啶醇治疗精神分裂激越症患者,其激越症状治疗及两种药物安全性方面相当,但齐拉西酮在治疗认知功能方面疗效更好,在引起锥体外系不良反应方面效果更安全,更具优势。

Objective To explore the comparison of curative effects and safety of ziprasidone and haloperidol in treatment of schizophrenia agitation.Methods Eighty patients with schizophrenia accompanied by agitation who were admitted and treated in our hospital from January 2017 to December 2018 were selected.They were randomly divided into the observation group and the control group,with 40 cases in each group.The control group was given haloperidol while the observation group was given ziprasidone.The positive and negative symptom scale(PANSS),positive and negative symptom scaleexcitation factor(PANSS-EC)and cognitive function scores(WMS,TMT)were evaluated in the two groups before and after treatment,and adverse reactions and events were recorded in the two groups.Results After treatment,the scores of PANSS and PANSS-EC in the two groups were better than those before treatment(P<0.05),but there were no differences between the two groups(P>0.05).After treatment,the scores of WMS and TMT in the observation group were better compared with those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups after treatment(P>0.05),but the incidence rate in observation group was slightly better than that in control group.Conclusion Ziprasidone and haloperidol for patients with schizophrenia agitation both have equivalent curative effects in treatment of agitation and drug safety,but ziprasidone has better efficacy in cognitive function treatment.It is safer and more advantageous in the aspects of extrapyramidal adverse reactions.